CPHIA 2025 met in Durban this week to discuss how African countries can become more self-reliant in health. The conference opened at the Durban International Convention Centre under the theme: “Moving Towards Self-Reliance to Achieve Universal Health Coverage and Health Security in Africa”. Delegates from more than 20 countries attended, including the African Union Commission, WHO, UNICEF, Gavi and the Global Fund.
On Thursday (23 October) Blade Nzimande spoke about a new pan‑African plan to expand regional manufacturing of vaccines and other drugs. The Africa CDC‑led plan is backed by the African Union, Afreximbank and Gavi with a US$3.2 billion investment. It aims for at least 60 per cent of vaccines used in Africa to be produced on the continent by 2040. Organisers said regional hubs, WHO‑quality standards and the African Medicines Agency will strengthen production and regulation.
Speakers also discussed funding pressures and a fall in overseas aid, and they called for African solutions and innovative financing. The conference will close on Saturday (25 October) with an outcome statement.
Difficult words
- leader — A person who guides or directs a group.leaders
- opportunity — A chance to do something good.opportunities
- job — A paid position of regular employment.jobs
- vaccine — A substance that helps prevent disease.
- produce — To make or create something.production
- community — A group of people living together.
- health — The state of being free from illness.healthcare
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What do you think about Africa becoming self-reliant in health?
- How can local solutions help with health problems?
- Why is vaccine production important for Africa?
Related articles
Emory study: 2023–24 COVID vaccine gives lasting antibodies
Emory University measured antibody responses in 24 people after the 2023–24 monovalent vaccine targeting Omicron XBB.1.5. The study found long-lasting antibodies, cross-reactive protection with the ancestral WA1 strain, and a 2.8-fold boost from immune imprinting.
